ArticleExperimental dermatology2013
Targeting iHSP 70 in vitiligo: a critical step for cure?
Article in Experimental dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Myron Gordon Award paper: Microbes, T-cell diversity and pigmentation.Pigment cell & melanoma research · 2021Review
- The convergence theory for vitiligo: A reappraisal.Experimental dermatology · 2019Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The group of Caroline Le Poole has produced a series of elegant papers suggesting an innovative rationale for the treatment of vitiligo by limiting native iHSP70 expression, with subsequent blockade of DC activation and melanocyte loss via T-cell-specific autoimmune responses. The proof of concept was made in a mouse model of the use of a mutant iHSP70 blunting this response. The comment emphasizes that in vitiligo, a skin and possibly epidermal defect underlies the initial steps leading to inflammation and subsequent melanocyte demise and discusses the relevance of targeting iHSP in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.